Total mesopancreas excision during minimally invasive pancreaticoduodenectomy (PD) represents a significant advancement in pancreatic cancer surgery, aiming to improve patient outcomes by enhancing the rate of R0 resections and reducing local recurrence. The mesopancreas, which contains lymphatic and perineural structures, is closely associated with tumor spread, making its excision critical for achieving optimal oncological results. The procedure begins with the Cattell-Braasch maneuver, which mobilizes the right colon and divides the mesentery root to improve exposure of key structures. Following this, the right posterior artery-first approach (AFA) is employed to expose the superior mesenteric artery (SMA), ensuring early assessment of tumor resectability and facilitating mesopancreas excision. Next, the small omentum is divided, and lymphadenectomy is performed to remove surrounding lymph nodes, further reducing the risk of recurrence. The pancreas is divided at the isthmus, exposing the SMA and completing the mesopancreas excision. The final phase involves isolating the jejunal loop and retrieving the en bloc specimen, which includes the pancreatic head, duodenum, and mesopancreas. With the advent of laparoscopic and robotic techniques, minimally invasive PD has become more widely adopted, offering advantages like reduced blood loss and quicker recovery. However, these approaches demand significant expertise due to their steep learning curve, limiting their availability to high-volume centers. Despite this, minimally invasive PD with total mesopancreas excision continues to show promise in improving the survival and quality of life of patients with pancreatic cancer.